LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBP&#945;-dependent enhancers in AML.

Cusan, Monica; Cai, Sheng F; Mohammad, Helai P; Krivtsov, Andrei; Chramiec, Alan; Loizou, Evangelia; Witkin, Matthew D; Smitheman, Kimberly N; Tenen, Daniel G; Ye, Min; Will, Britta; Steidl, Ulrich; Kruger, Ryan G; Levine, Ross L; Rienhoff, Hugh Y; Koche, Richard P; Armstrong, Scott A

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Cusan, Monica; Cai, Sheng F; Mohammad, Helai P; Krivtsov, Andrei; Chramiec, Alan; Loizou, Evangelia; Witkin, Matthew D; Smitheman, Kimberly N; Tenen, Daniel G; Ye, Min; Will, Britta; Steidl, Ulrich; Kruger, Ryan G; Levine, Ross L; Rienhoff, Hugh Y; Koche, Richard P; Armstrong, Scott A.

Afiliación

Cusan M; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Cai SF; University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
Mohammad HP; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Krivtsov A; GlaxoSmithKline, Newark, NJ.
Chramiec A; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Loizou E; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and.
Witkin MD; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Smitheman KN; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Tenen DG; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Ye M; GlaxoSmithKline, Newark, NJ.
Will B; Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Steidl U; Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Kruger RG; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY; and.
Levine RL; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY; and.
Rienhoff HY; GlaxoSmithKline, Newark, NJ.
Koche RP; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Armstrong SA; Imago Biosciences, Inc., San Francisco, CA.

Blood ; 131(15): 1730-1742, 2018 04 12.

Article en En | MEDLINE | ID: mdl-29453291

Asunto(s)

Proteínas Potenciadoras de Unión a CCAAT/metabolismo; Inhibidores Enzimáticos/farmacología; Histona Demetilasas/antagonistas & inhibidores; Leucemia Bifenotípica Aguda/tratamiento farmacológico; Proteínas de Neoplasias/antagonistas & inhibidores; Neoplasias Experimentales/tratamiento farmacológico; Proteínas Proto-Oncogénicas/metabolismo; Transactivadores/metabolismo; Animales; Proteínas Potenciadoras de Unión a CCAAT/genética; Histona Demetilasas/genética; Histona Demetilasas/metabolismo; Leucemia Bifenotípica Aguda/genética; Leucemia Bifenotípica Aguda/metabolismo; Leucemia Bifenotípica Aguda/patología; Ratones; Proteínas de Neoplasias/genética; Proteínas de Neoplasias/metabolismo; Neoplasias Experimentales/genética; Neoplasias Experimentales/metabolismo; Neoplasias Experimentales/patología; Proteínas Proto-Oncogénicas/genética; Elementos de Respuesta; Transactivadores/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Bifenotípica Aguda / Transactivadores / Proteínas Proto-Oncogénicas / Proteínas Potenciadoras de Unión a CCAAT / Inhibidores Enzimáticos / Histona Demetilasas / Proteínas de Neoplasias / Neoplasias Experimentales Límite: Animals Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google